On December 20, 2023, Thiogenesis Therapeutics, Corp., closed the transaction. The company issued 417,000 common shares at an issue price of CAD 0.75 per share for gross proceeds of CAD 312,750. The company paid finder's fees of CAD 21,892 and 29,190 non-transferable finders' options to eligible persons in compliance with applicable securities laws and TSX Venture Exchange.

Each finder's option entitles the holder to acquire one common share at a price of CAD 0.75 for a period of two (2) years following closing. All securities issued pursuant to this Offering will be subject to resale restrictions for a period of four months and one day from closing under applicable securities legislation. The Offering is subject to the final acceptance of the Exchange.

The company paid finder's fees of CAD 307,186.27 and 409,582 warrants. Each finder's warrant entitles the holder to purchase one common share at a price of CAD 0.75 for a period of two years from the date of issuance. The transaction involved participation from 79 placees, one insider for CAD 50,000, and nine pro groups for CAD 836,667.

The TSX Venture Exchange has accepted for filing documentation with respect to the transaction.